Xiawei Wei
Impact in
- Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Cancer Research top 0.5%
Papers in
- Immunology 80
- Immune cells in cancer 30
- Immunotherapy and Immune Responses 29
-
- SARS-CoV-2 and COVID-19 Research 30
- COVID-19 Clinical Research Studies 16
- Co-authors
- Yuquan Wei (76 shared papers)Manni Wang (20 shared papers)Weiqi Hong (34 shared papers)Xuelei Ma (17 shared papers)Tianxia Lan (19 shared papers)Minyang Fu (5 shared papers)Yong Peng (7 shared papers)Yuhe Huang (3 shared papers)
- Journals
- Signal Transduction and Targeted Therapy (15 papers)Journal of Hematology & Oncology (11 papers)Cell Proliferation (10 papers)Molecular Cancer (9 papers)Cancer Letters (8 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Xiawei Wei
239 papers receiving 18.6k citations
Xiawei Wei's Hit Papers
Peers
Comparison fields: 5 of 171
- Immunology 3.9k
- Cancer Research 1.9k
- Oncology 3.4k
- Molecular Biology 7.7k
- Biomaterials 1.2k
Countries citing papers authored by Xiawei Wei
This map shows the geographic impact of Xiawei Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiawei Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiawei Wei more than expected).
Fields of papers citing papers by Xiawei Wei
This network shows the impact of papers produced by Xiawei Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiawei Wei. The network helps show where Xiawei Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiawei Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 247 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Targeting PI3K in cancer: mechanisms and advances in clinical trials Hit paper breakdown → | 2019 | 1215 |
| 2 | Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials Hit paper breakdown → | 2019 | 799 |
| 3 | Targeting TGF-β signal transduction for fibrosis and cancer therapy Hit paper breakdown → | 2022 | 791 |
| 4 | The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis Hit paper breakdown → | 2022 | 681 |
| 5 | Cancer vaccines as promising immuno-therapeutics: platforms and current progress Hit paper breakdown → | 2022 | 553 |
| 6 | A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome Hit paper breakdown → | 2020 | 508 |
| 7 | Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets Hit paper breakdown → | 2022 | 406 |
| 8 | Cellular Toxicity and Immunological Effects of Carbon-based Nanomaterials Hit paper breakdown → | 2019 | 403 |
| 9 | AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications Hit paper breakdown → | 2019 | 385 |
| 10 | SARS‐CoV‐2 Omicron variant: Characteristics and prevention Hit paper breakdown → | 2021 | 376 |
| 11 | mRNA vaccine: a potential therapeutic strategy Hit paper breakdown → | 2021 | 318 |
| 12 | 2020 | 305 | |
| 13 | 2020 | 282 | |
| 14 | 2017 | 277 | |
| 15 | 2019 | 276 | |
| 16 | 2016 | 270 | |
| 17 | Mesenchymal stem/stromal cells in cancer therapy Hit paper breakdown → | 2021 | 269 |
| 18 | 2019 | 263 | |
| 19 | Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting Hit paper breakdown → | 2021 | 262 |
| 20 | 2016 | 261 |
About Xiawei Wei
Xiawei Wei is a scholar working on Immunology, Infectious Diseases, Molecular Biology, Oncology and Animal Science and Zoology, having authored 247 papers that have together received 18.8k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (34 papers), SARS-CoV-2 and COVID-19 Research (30 papers), Immune cells in cancer (30 papers), Immunotherapy and Immune Responses (29 papers), Advanced biosensing and bioanalysis techniques (16 papers), COVID-19 Clinical Research Studies (16 papers), Nanoplatforms for cancer theranostics (15 papers) and Animal Virus Infections Studies (14 papers). The work is most often cited by research in Immunology (3.9k citations), Cancer Research (1.9k citations), Oncology (3.4k citations), Molecular Biology (7.7k citations) and Biomaterials (1.2k citations). Xiawei Wei has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Yuquan Wei, Manni Wang, Weiqi Hong, Xuelei Ma, Tianxia Lan, Minyang Fu, Yong Peng, Yuhe Huang, Ji Nie and Jing Yang. Their work appears in journals such as Signal Transduction and Targeted Therapy, Journal of Hematology & Oncology, Cell Proliferation, Molecular Cancer and Cancer Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.